4-Cyano-2-fluorobenzene-1-sulfonamide, 95+%, 500mg

1-(2,6-dimethoxyphenyl)ethanone, 95.0%, 25g

1-(2-Methoxyphenyl)-1H-pyrazole, 95.0%, 1g

7-CYCLOPENTYL-5-(4-PHENOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINE, 95%, 100mg

E-Plan fase EPLPHi 20x/0,40 objetivo IOS corregido al infinito. Distancia de trabajo 2,61 mm

tert-butyl N-[(2-aminophenyl)methyl]-N-ethylcarbamate, 97%, 100mg

5-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, 95.0%, 5g

4-Bromo-1-methyl-3-(pyrrolidin-1-yl)-1h-pyrazole, 98%, 1g

1-(2,7-Dibromospiro[fluorene-9,4'-piperidin]-1'-yl)ethan-1-one, 97%, 100mg

2-(Bis(phosphonomethyl)amino)acetic acid, 95.0%, 5g

6-mercapto-1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, 95.0%, 1g

(S)-3-AMINO-3-(3-FLUOROPHENYL)PROPANOIC ACID HCL, 97.0%, 10g

Ethyl 3-chloroimidazo[1,5-a]pyridine-1-carboxylate, 95.0%, 100mg